FERRER’S PUBLIC BENEFIT PHILOSOPHY
At Ferrer we want to promote a new way of doing business and a responsible way of being in the world. We want to make a positive impact in society while running a successful pharmaceutical enterprise. Our business is not an end in itself, but a means to generate positive global impact. Our conviction is such that the company’s strategic plan consists of three pillars that define what we want to achieve: great people, a livable planet, and social justice. In its mission, Ferrer has exceeded global B Corp standards in terms of social and environment performance, transparency, and corporate responsibility – and in all the territories for which it has a direct presence (https://ferrer.com/en/Ferrer-becomes-a-bcorp). Over the last four years, the company has placed increasing focus on achieving transformation as a positive global and social impact organization. Our purpose, our strategy and our achievements are present in our corporate identity and slogan: “Ferrer for good”.
FERRER’S GROWTH AREAS: RARE PULMONARY AND NEUROLOGY DISORDERS
Ferrer is a privately owned, multinational pharma company with a growing presence in rare diseases. Ferrer has built a franchise in pulmonary hypertension in Europe and has initiated another business initiative in amyotrophic lateral sclerosis, beginning with a partnership focused on clinical development of an oral therapy in Europe. Our partnering activities are centered on in-licensing of clinical stage programs in rare neurology and pulmonary disorders, and out-licensing of non-core programs. As an integrated company, Ferrer maintains streamlined, end-to-end operating capabilities. Its gendered-balanced executive team is currently leading Ferrer’s transformation journey as it aims to research, develop, and commercialize transformative solutions that make a positive impact in society.